Regeneron Pharmaceuticals Aktie News

JP Morgan analysts see an “attractive setup” for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares, believing the company's Dupixent and Eylea drugs and cash on hand alone support valuation at current levels.  In a note to clients on Friday, the analysts wrote that they expect several catalysts for the company over the next three to six months, including Phase 3 trial results for LAG3 melanoma...

Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent expirations position the company well for future revenue and margin expansion. Financials remain solid with significant cash reserves, low debt, and shares trading at an undemanding valuation rela...

TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Over the past couple of years, Moderna (MRNA 3.39%) and Regeneron Pharmaceuticals (REGN -0.62%) have encountered company-specific headwinds that have sunk their stock prices. The former is down by 75% over this period, while the latter has dropped 32%.

Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. So, sales of Regeneron's PD-1 inhibitor amounted to $377 million in the second quarter of 2025, an increase of 32.3% quarter-on-quarter. Despite the "doubts and fear" clouding investors' minds, Rege...

FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-density lipoprotein cholesterol (LDL-C) Initial Evkeeza approval based on placebo-controlled trial showing Evkeeza, when added to standard lipid-lowering therapies, could lower LDL-C by about 50% compare...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.

Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with Dupixent, EYLEA HD, Libtayo, and Lynozyfic all contributing to performance. Despite regulatory delays and competition, the company's pipeline and new indications for key drugs support long-term gro...